Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Pediatric Monogenic Diabetes: A Unique Challenge and Opportunity.

Harris A, Naylor RN.

Pediatr Ann. 2019 Aug 1;48(8):e319-e325. doi: 10.3928/19382359-20190730-02.

PMID:
31426100
2.

Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2).

Gregory JM, Smith TJ, Slaughter JC, Mason HR, Hughey CC, Smith MS, Kandasamy B, Greeley SAW, Philipson LH, Naylor RN, Letourneau LR, Abumrad NN, Cherrington AD, Moore DJ.

Diabetes. 2019 Aug;68(8):1565-1576. doi: 10.2337/db19-0324. Epub 2019 May 15.

PMID:
31092478
3.

GCK-MODY in the US Monogenic Diabetes Registry: Description of 27 unpublished variants.

Sanyoura M, Letourneau L, Knight Johnson AE, Del Gaudio D, Greeley SAW, Philipson LH, Naylor RN.

Diabetes Res Clin Pract. 2019 May;151:231-236. doi: 10.1016/j.diabres.2019.04.017. Epub 2019 May 4.

PMID:
31063852
4.

Management and pregnancy outcomes of women with GCK-MODY enrolled in the US Monogenic Diabetes Registry.

Dickens LT, Letourneau LR, Sanyoura M, Greeley SAW, Philipson LH, Naylor RN.

Acta Diabetol. 2019 Apr;56(4):405-411. doi: 10.1007/s00592-018-1267-z. Epub 2018 Dec 11.

PMID:
30535721
5.

Clinical Management of Women with Monogenic Diabetes During Pregnancy.

Dickens LT, Naylor RN.

Curr Diab Rep. 2018 Feb 15;18(3):12. doi: 10.1007/s11892-018-0982-8. Review.

6.

Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis.

Laiteerapong N, Cooper JM, Skandari MR, Clarke PM, Winn AN, Naylor RN, Huang ES.

Ann Intern Med. 2018 Feb 6;168(3):170-178. doi: 10.7326/M17-0537. Epub 2017 Dec 12.

7.

Hypoglycemia in sulfonylurea-treated KCNJ11-neonatal diabetes: Mild-moderate symptomatic episodes occur infrequently but none involving unconsciousness or seizures.

Lanning MS, Carmody D, Szczerbiński Ł, Letourneau LR, Naylor RN, Greeley SAW.

Pediatr Diabetes. 2018 May;19(3):393-397. doi: 10.1111/pedi.12599. Epub 2017 Dec 5.

8.

Diabetes Presentation in Infancy: High Risk of Diabetic Ketoacidosis.

Letourneau LR, Carmody D, Wroblewski K, Denson AM, Sanyoura M, Naylor RN, Philipson LH, Greeley SAW.

Diabetes Care. 2017 Oct;40(10):e147-e148. doi: 10.2337/dc17-1145. Epub 2017 Aug 4. No abstract available.

9.

Patients with KCNJ11-related diabetes frequently have neuropsychological impairments compared with sibling controls.

Carmody D, Pastore AN, Landmeier KA, Letourneau LR, Martin R, Hwang JL, Naylor RN, Hunter SJ, Msall ME, Philipson LH, Scott MN, Greeley SA.

Diabet Med. 2016 Oct;33(10):1380-6. doi: 10.1111/dme.13159. Epub 2016 Jun 22.

10.

GCK-MODY in the US National Monogenic Diabetes Registry: frequently misdiagnosed and unnecessarily treated.

Carmody D, Naylor RN, Bell CD, Berry S, Montgomery JT, Tadie EC, Hwang JL, Greeley SA, Philipson LH.

Acta Diabetol. 2016 Oct;53(5):703-8. doi: 10.1007/s00592-016-0859-8. Epub 2016 Apr 22.

11.

Insulin dosing in pediatric diabetic ketoacidosis: where to start?

Carmody D, Naylor RN, Philipson LH.

JAMA. 2015 Jun 9;313(22):2274-5. doi: 10.1001/jama.2015.135. No abstract available.

PMID:
26057288
12.

Role of noninsulin therapies alone or in combination in chromosome 6q24-related transient neonatal diabetes: sulfonylurea improves but does not always normalize insulin secretion.

Carmody D, Beca FA, Bell CD, Hwang JL, Dickens JT, Devine NA, Mackay DJ, Temple IK, Hays LR, Naylor RN, Philipson LH, Greeley SA.

Diabetes Care. 2015 Jun;38(6):e86-7. doi: 10.2337/dc14-3056. No abstract available.

13.

Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes.

Thurber BW, Carmody D, Tadie EC, Pastore AN, Dickens JT, Wroblewski KE, Naylor RN, Philipson LH, Greeley SA; United States Neonatal Diabetes Working Group.

Diabetologia. 2015 Jul;58(7):1430-5. doi: 10.1007/s00125-015-3593-9. Epub 2015 Apr 17.

14.

Adolescent non-adherence reveals a genetic cause for diabetes.

Carmody D, Lindauer KL, Naylor RN.

Diabet Med. 2015 Jun;32(6):e20-3. doi: 10.1111/dme.12669.

15.

Sulfonylurea treatment before genetic testing in neonatal diabetes: pros and cons.

Carmody D, Bell CD, Hwang JL, Dickens JT, Sima DI, Felipe DL, Zimmer CA, Davis AO, Kotlyarevska K, Naylor RN, Philipson LH, Greeley SA.

J Clin Endocrinol Metab. 2014 Dec;99(12):E2709-14. doi: 10.1210/jc.2014-2494.

16.

Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications.

Naylor RN, John PM, Winn AN, Carmody D, Greeley SA, Philipson LH, Bell GI, Huang ES.

Diabetes Care. 2014;37(1):202-9. doi: 10.2337/dc13-0410. Epub 2013 Sep 11.

17.

Neonatal diabetes: an expanding list of genes allows for improved diagnosis and treatment.

Greeley SA, Naylor RN, Philipson LH, Bell GI.

Curr Diab Rep. 2011 Dec;11(6):519-32. doi: 10.1007/s11892-011-0234-7. Review.

18.

Creation of the Web-based University of Chicago Monogenic Diabetes Registry: using technology to facilitate longitudinal study of rare subtypes of diabetes.

Greeley SA, Naylor RN, Cook LS, Tucker SE, Lipton RB, Philipson LH.

J Diabetes Sci Technol. 2011 Jul 1;5(4):879-86.

19.

Genetics and pathophysiology of neonatal diabetes mellitus.

Naylor RN, Greeley SA, Bell GI, Philipson LH.

J Diabetes Investig. 2011 Jun 5;2(3):158-69. doi: 10.1111/j.2040-1124.2011.00106.x. Review.

20.

Neonatal diabetes mellitus: a model for personalized medicine.

Greeley SA, Tucker SE, Naylor RN, Bell GI, Philipson LH.

Trends Endocrinol Metab. 2010 Aug;21(8):464-72. doi: 10.1016/j.tem.2010.03.004. Epub 2010 Apr 29. Review.

Supplemental Content

Loading ...
Support Center